Further, 13F3 (anti-VISTA monotherapy) can effectively improve the tumor microenvironment, reduce the number of tumor specific Treg cells and MDSCs, increase the number of TILs, and promote the function of T cells in melanoma and bladder carcinoma mouse models [34, 78]. This evidence concerns the gene VSIR and melanoma.